Share price · XENE
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when XENE's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 18 Sep 2026-30.7%
- 26 Aug 2026+5.6%
- 8 Jul 2026+10.4%
Nothing announced by XENE that day or the session before.
- 9 Mar 2026+49.6%
- 27 Feb 2026-3.8%
- 24 Feb 2026+4.8%
Nothing announced by XENE that day or the session before.
- 5 Jan 2026-6.1%
Nothing announced by XENE that day or the session before.
Share of unusual movement by asset
For each asset, the share of XENE's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | Kv7 potassium channelSmall molecule | Major Depressive DisorderEpilepsy Focal Onset Seizures, Primary Generalized Tonic-Clonic Seizures |
Upcoming events
(7 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (3)
2028 (2)
2029 (1)
June 2029 (1)
What to watch
2033 (1)
April 2033 (1)
What to watch
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $0 | $96M | $83M+ $868M short-term inv. | $110M-$90M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $0 | $99M | $120M+ $811M short-term inv. | $111M-$95M operating cash flow | report ↗ |
| 2026-Q1 | $0 | $89M | $546M+ $549M short-term inv. | $102M-$89M operating cash flow | report ↗ |
| 2025-Q3 | $0 | $77M | $105M+ $358M short-term inv. | $91M-$72M operating cash flow | report ↗ |
| 2025-Q2 | $0 | $75M | $135M+ $352M short-term inv. | $85M-$64M operating cash flow | report ↗ |
| 2025-Q1 | $7.5M | $61M | $117M+ $433M short-term inv. | $65M-$62M operating cash flow | report ↗ |
| 2024-Q3 | $0 | $57M | $88M+ $566M short-term inv. | $63M-$51M operating cash flow | report ↗ |
| 2024-Q2 | $0 | $50M | $137M+ $585M short-term inv. | $58M-$33M operating cash flow | report ↗ |
| 2024-Q1 | $0 | $44M | $59M+ $641M short-term inv. | $48M-$43M operating cash flow | report ↗ |
| 2023-Q3 | — | $43M | $100M+ $427M short-term inv. | $48M-$42M operating cash flow | report ↗ |
| 2023-Q2 | — | $44M | $65M+ $475M short-term inv. | $47M-$33M operating cash flow | report ↗ |
| 2023-Q1 | — | $40M | $70M+ $458M short-term inv. | $42M-$34M operating cash flow | report ↗ |
| 2022-Q3 | $0.1M | $29M | $103M+ $535M short-term inv. | $37M-$30M operating cash flow | report ↗ |
| 2022-Q2 | $0.5M | $22M | $370M+ $418M short-term inv. | $31M-$17M operating cash flow | report ↗ |
| 2022-Q1 | $8.8M | $19M | $117M+ $421M short-term inv. | $20M-$18M operating cash flow | report ↗ |
| 2021-Q3 | $8.1M | $19M | $88M+ $162M short-term inv. | $15M-$15M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $7.5M | $301M | $199M+ $350M short-term inv. | $86M-$279M operating cash flow | report ↗ |
Xenon reported fiscal 2025 revenue of $7.5M, versus $0M YoY. R&D expense was $300.94M, up 43.0% YoY, cash and equivalents were $199.16M, and cash plus marketable securities totaled $586.0M at Dec. 31, 2025. Net loss was $345.91M, with a reported quarterly net burn of $345.91M.
Management guided that pro forma cash of $716.0M, including ATM proceeds, funds operations into the second half of 2027. Pipeline milestones include Phase 3 X-TOLE2 topline data for azetukalner in focal onset seizures expected in the first half of March 2026, an anticipated NDA submission in H2 2026, X-NOVA2 MDD topline data expected in H1 2027, and Phase 1 data for XEN1701 and XEN1120 expected in 2026. Enrollment continues across X-TOLE3, X-ACKT, X-NOVA3, and X-CEED; 48-month X-TOLE open-label extension data were presented at AES, and a partnered Phase 1 study of NBI-921355 with Neurocrine is ongoing.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $0 | $210M | $143M+ $484M short-term inv. | $59M-$181M operating cash flow | report ↗ |
| 2023-FY | $0 | $168M | $149M+ $489M short-term inv. | $46M-$145M operating cash flow | report ↗ |
| 2022-FY | $9.4M | $106M | $57M+ $535M short-term inv. | $31M-$98M operating cash flow | report ↗ |
| 2021-FY | $18M | $75M | $176M+ $376M short-term inv. | $20M-$70M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 2 purchases ($1.7M), 26 sales ($22.0M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-10-15 | Kelly Thomas Patrick · Chief Financial Officer | Option exercise | 7,500 | — | — | Form 4 |
| 2026-10-15 | Kelly Thomas Patrick · Chief Financial Officer | Option exercise (derivative) | 7,500 | — | — | Form 4 |
| 2026-09-30 | MORTIMER IAN · director, PRESIDENT & CEO | Open-market purchase | 30,000 | $37.38 | $1.1M | Form 4 |
| 2026-09-30 | Kelly Thomas Patrick · Chief Financial Officer | Open-market purchase | 15,000 | $37.32 | $560K | Form 4 |
| 2026-09-01 | Svoronos Dawn · director | Option exercise | 5,144 | $8.15 | $42K | Form 4 |
| 2026-09-01 | Svoronos Dawn · director | Option exercise (derivative) | 5,144 | — | — | Form 4 |
| 2026-08-28 | KENNEY CHRISTOPHER JOHN · Chief Medical Officer | Open-market sale | 6,368 | $60.17 | $383K | Form 4 |
| 2026-08-28 | KENNEY CHRISTOPHER JOHN · Chief Medical Officer | Open-market sale | 700 | $60.98 | $43K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 288 reporting institutions held 100.3M shares ($5.6B, 103.8% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | FMR LLC | 10,818,491 | $629.1M |
| 2 | Avoro Capital Advisors LLC | 5,777,777 | $336.0M |
| 3 | BlackRock, Inc. | 5,640,118 | $328.0M |
| 4 | WELLINGTON MANAGEMENT GROUP LLP | 4,829,641 | $280.8M |
| 5 | Driehaus Capital Management LLC | 4,491,653 | $261.2M |
| 6 | Polar Capital Holdings Plc | 4,405,312 | $256.2M |
| 7 | JANUS HENDERSON GROUP PLC | 4,175,982 | $242.9M |
| 8 | Capital International Investors | 2,674,727 | $155.5M |
| 9 | CITADEL ADVISORS LLC | 2,652,990 | $154.3M |
| 10 | JPMORGAN CHASE & CO | 1,923,610 | $106.9M |
| 11 | STATE STREET CORP | 1,720,533 | $100.0M |
| 12 | Affinity Asset Advisors, LLC | 1,675,000 | $97.4M |
| 13 | DEERFIELD MANAGEMENT COMPANY, L.P. | 1,615,696 | $94.0M |
| 14 | Holocene Advisors, LP | 1,518,686 | $88.3M |
| 15 | WESTFIELD CAPITAL MANAGEMENT CO LP | 1,401,483 | $81.5M |